Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

breast cancer

  • Home
  • breast cancer
  • Page 4
Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
Posted inClinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

Posted by MedXY By MedXY 08/05/2025
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.
Read More
One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth
Posted inFamily Medicine & Nutrition Medical News news Specialties

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth

Posted by MedXY By MedXY 08/04/2025
A single session of resistance or high-intensity interval training boosts anti-cancer myokines in breast cancer survivors, significantly suppressing cancer cell growth in vitro.
Read More
Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial
Posted inClinical Updates news Oncology Specialties

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

Posted by MedXY By MedXY 08/02/2025
Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.
Read More
Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?
Posted inClinical Updates news Oncology Specialties

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

Posted by MedXY By MedXY 08/01/2025
A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.
Read More
Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study
Posted inClinical Updates news Oncology Orthopedics Specialties

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

Posted by MedXY By MedXY 07/31/2025
Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.
Read More
Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies
Posted inClinical Updates news Oncology Specialties

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

Posted by MedXY By MedXY 07/30/2025
Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.
Read More
Removing Out-of-Pocket Costs Increases Access to 3D Mammograms
Posted innews OB/GYN & Women's Health Specialties

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms

Posted by MedXY By MedXY 07/29/2025
Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.
Read More
Understanding Hormone Therapy and Breast Cancer Risk in Younger Women
Posted innews OB/GYN & Women's Health Oncology Specialties

Understanding Hormone Therapy and Breast Cancer Risk in Younger Women

Posted by MedXY By MedXY 07/29/2025
Recent research highlights that estrogen-only hormone therapy may reduce breast cancer risk in women under 55, while combined estrogen-progestin therapy could increase risk.
Read More

Posts pagination

Previous page 1 2 3 4
  • Ripasudil After DSO in Fuchs Endothelial Corneal Dystrophy: A Randomized Trial Signals a New Path to Corneal Recovery
  • Retinal Microvascular Clues to Alzheimer Disease: What Swept-Source OCT Angiography Reveals About Neurovascular Dysfunction
  • Calm in the Clinic? Digital Mindfulness Shows Promise for Anxiety and Depression in Non-infectious Uveitis
  • MDASI-HN Symptom Profiling for Early Risk Stratification of Hypoglossal Neuropathy in Oropharyngeal Cancer Survivors
  • Low-Yield or High-Value? Preoperative Cardiac Workup in Children With Very Severe OSA
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in